{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:03:51Z","timestamp":1793729031461,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with coronary ectasia (CAE) have an increased risk of major cardiovascular events (MACE). Current preventive treatments are uncertain, with oral anticoagulants often prescribed based on limited retrospective studies. Our aim is to help address the question: what is the most appropriate treatment?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a retrospective cohort of patients with an ACS and CAE in a single center in Mexico City, two groups were observed based on the treatment at discharge: dual antiplatelet therapy (group 1) and anticoagulation with either a VKA or a DOAC, regardless of antiplatelet therapy (group 2). The main outcome was MACE, which was a composite of all-cause mortality, reinfarction, and ischemic stroke at 4.5\u00a0years follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 354 patients admitted for ACS and CAE were included. 228 (64.4%) patients were classified in the DAPT group and 126 (35.5%) in the anticoagulants group. The DAPT group had higher type 2 diabetes rates, NSTEMI presentation, and lower-grade ectasia. The anticoagulation group had higher STEMI presentation and higher-grade ectasia. The DAPT group had 33 (14.5%) events of MACE, whereas the anticoagulation group had 16 (13.1%) events. Anticoagulants were not associated with a risk reduction of the primary endpoint (HR 0.95; 95% CI, 0.47\u20131.54;\n                      <jats:italic>p\u2009=\u2009<\/jats:italic>\n                      0.59), nor any of the individual components.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective cohort study showed similar effectiveness between DAPT and anticoagulation in patients with ACS and CAE for preventing MACE, and lower bleeding risk. Further research is needed to identify optimal candidates for each antithrombotic regime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                    <jats:p>DAPT: double antiplatelet therapy, HR: hazard ratio<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-025-07784-0","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:12:25Z","timestamp":1758705145000},"page":"1021-1033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5145-0680","authenticated-orcid":false,"given":"Fabio","family":"Solis-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-8805","authenticated-orcid":false,"given":"Ximena Latapi-Ruiz","family":"Esparza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7672-4587","authenticated-orcid":false,"given":"Hannah Priscila","family":"Guzman-Solorzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9915-2597","authenticated-orcid":false,"given":"Monserrat","family":"Villalobos-Pedroza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4116-2359","authenticated-orcid":false,"given":"Luis Angel","family":"Morales-Villamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1046-5184","authenticated-orcid":false,"given":"Braiana Angeles","family":"Diaz-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1809-5007","authenticated-orcid":false,"given":"Sarai","family":"Hernandez-Pastrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-4869","authenticated-orcid":false,"given":"Rodrigo","family":"Gopar-Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-5465","authenticated-orcid":false,"given":"Eduardo A.","family":"Arias-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8039-8885","authenticated-orcid":false,"given":"Luis Alfonso","family":"Marroqu\u00edn-Donday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3275-7115","authenticated-orcid":false,"given":"Gian Manuel","family":"Jim\u00e9nez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-6973","authenticated-orcid":false,"given":"Daniel","family":"Sierra-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-0051","authenticated-orcid":false,"given":"Diego","family":"Araiza-Garaygordobil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5942-4102","authenticated-orcid":false,"given":"Alexandra","family":"Arias-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"7784_CR1","unstructured":"Mavrogeni S. Coronary artery ectasia: diagnosis and treatment [Internet]. Available from: https:\/\/www.escardio.org\/Journals\/E-Journal-of-Cardiology-Practice\/Volume-8\/Coronary-artery-ectasia-diagnosis-and-treatment"},{"issue":"9","key":"7784_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/0003319716665690","volume":"68","author":"Y Luo","year":"2017","unstructured":"Luo Y, Tang J, Liu X, et al. Coronary artery aneurysm differs from coronary artery ectasia: angiographic characteristics and cardiovascular risk factor analysis in patients referred for coronary angiography. Angiology. 2017;68(9):823\u201330.","journal-title":"Angiology"},{"issue":"2","key":"7784_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0002-9149(76)90315-5","volume":"37","author":"JE Markis","year":"1976","unstructured":"Markis JE, Joffe CD, Cohn PF, et al. Clinical significance of coronary arterial ectasia. Am J Cardiol. 1976;37(2):217\u201322.","journal-title":"Am J Cardiol"},{"issue":"6","key":"7784_CR4","first-page":"7530","volume":"157","author":"E Rojas-Mil\u00e1n","year":"2021","unstructured":"Rojas-Mil\u00e1n E, Morales De Le\u00f3n CE, Garc\u00eda-Rinc\u00f3n A, et al. Factores de riesgo cardiovascular asociados a ectasia coronaria e infarto agudo de miocardio. Gac M\u00e9dica M\u00e9xico. 2021;157(6):7530.","journal-title":"Gac M\u00e9dica M\u00e9xico."},{"issue":"3","key":"7784_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijcard.2008.05.071","volume":"130","author":"AP Antoniadis","year":"2008","unstructured":"Antoniadis AP, Chatzizisis YS, Giannoglou GD. Pathogenetic mechanisms of coronary ectasia. Int J Cardiol. 2008;130(3):335\u201343.","journal-title":"Int J Cardiol"},{"issue":"6","key":"7784_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/CRD.0b013e3181852659","volume":"16","author":"P Cohen","year":"2008","unstructured":"Cohen P, O\u2019Gara PT. Coronary artery aneurysms: a review of the natural history, pathophysiology, and management. Cardiol Rev. 2008;16(6):301\u20134.","journal-title":"Cardiol Rev"},{"key":"7784_CR7","doi-asserted-by":"crossref","unstructured":"Vega-Gomez J, De Los R\u00edos Arce L, S\u00e1nchez-Mu\u00f1oz F, et al. Association between mRNA 133b and Patients with Coronary Artery Ectasia and Acute Coronary Syndrome. 2023.","DOI":"10.21203\/rs.3.rs-2921437\/v1"},{"issue":"13_Supplement","key":"7784_CR8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S0735-1097(24)03219-4","volume":"83","author":"O-U Preciado-Gutierrez","year":"2024","unstructured":"Preciado-Gutierrez O-U, Vega J, et al. Association between MIRNA-133B and coronary artery ectasia in patients with acute coronary syndrome. J Am Coll Cardiol. 2024;83(13_Supplement):1229\u20131229.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7784_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0003319718782807","volume":"70","author":"S Liang","year":"2019","unstructured":"Liang S, Zhang Y, Gao X, et al. Is coronary artery ectasia a thrombotic disease? Angiology. 2019;70(1):62\u20138.","journal-title":"Angiology"},{"issue":"6","key":"7784_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MCA.0b013e3282a30665","volume":"18","author":"AS Yasar","year":"2007","unstructured":"Yasar AS, Erbay AR, Ayaz S, et al. Increased platelet activity in patients with isolated coronary artery ectasia. Coron Artery Dis. 2007;18(6):451\u20134.","journal-title":"Coron Artery Dis"},{"issue":"6","key":"7784_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/pin.12921","volume":"70","author":"Y Asada","year":"2020","unstructured":"Asada Y, Yamashita A, Sato Y, et al. Pathophysiology of atherothrombosis: mechanisms of thrombus formation on disrupted atherosclerotic plaques. Pathol Int. 2020;70(6):309\u201322.","journal-title":"Pathol Int"},{"issue":"6","key":"7784_CR12","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/joim.12296","volume":"276","author":"L Badimon","year":"2014","unstructured":"Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med. 2014;276(6):618\u201332.","journal-title":"J Intern Med"},{"issue":"1","key":"7784_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/eurheartj\/ehad720","volume":"45","author":"CCFMJ Baaten","year":"2024","unstructured":"Baaten CCFMJ, Nagy M, Bergmeier W, et al. Platelet biology and function: plaque erosion vs rupture. Eur Heart J. 2024;45(1):18\u201331.","journal-title":"Eur Heart J"},{"issue":"6","key":"7784_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1023\/B:CAIM.0000004339.30038.8d","volume":"19","author":"A Dogan","year":"2003","unstructured":"Dogan A, Tunc B, Ergene O, et al. Evaluation of overall fibrinolytic activity in patients with coronary artery ectasia: Global fibrinolytic capacity. Int J Card Imaging. 2003;19(6):465\u201371.","journal-title":"Int J Card Imaging"},{"issue":"10","key":"7784_CR15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.hlc.2016.12.006","volume":"26","author":"V Bogana Shanmugam","year":"2017","unstructured":"Bogana Shanmugam V, Psaltis PJ, Wong DT, et al. Outcomes after primary percutaneous coronary intervention for ST-Elevation myocardial infarction caused by ectatic infarct related arteries. Heart Lung Circ. 2017;26(10):1059\u201368.","journal-title":"Heart Lung Circ."},{"issue":"7","key":"7784_CR16","first-page":"1219","volume":"93","author":"P Gunasekaran","year":"2019","unstructured":"Gunasekaran P, Stanojevic D, Drees T, et al. Prognostic significance, angiographic characteristics and impact of antithrombotic and anticoagulant therapy on outcomes in high versus low grade coronary artery ectasia: a long-term follow-up study. Catheter Cardiovasc Interv. 2019;93(7):1219\u201327.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"12","key":"7784_CR17","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1161\/ATVBAHA.117.309683","volume":"37","author":"T Doi","year":"2017","unstructured":"Doi T, Kataoka Y, Noguchi T, et al. Coronary artery ectasia predicts future cardiac events in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2017;37(12):2350\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"7784_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1055\/s-0039-1692706","volume":"28","author":"R Pranata","year":"2019","unstructured":"Pranata R, Yonas E, Chintya V, et al. Is anticoagulant necessary in patients with coronary artery ectasia presenting with acute coronary syndrome? A systematic review of case reports. Int J Angiol. 2019;28(4):231\u20136.","journal-title":"Int J Angiol"},{"key":"7784_CR19","doi-asserted-by":"crossref","unstructured":"Thygesen K, Alpert JS, Jaffe AS et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation [Internet]. 2018 Nov 13 [cited 2024 Jun 11];138(20).","DOI":"10.1161\/CIR.0000000000000617"},{"issue":"10","key":"7784_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/01.CIR.102.10.1193","volume":"102","author":"E Braunwald","year":"2000","unstructured":"Braunwald E, Antman EM, Beasley JW, et al. ACC\/AHA guidelines for the management of patients with unstable angina and non\u2013ST-segment elevation myocardial infarction: executive summary and recommendations: A report of the American college of cardiology\/American heart association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000;102(10):1193\u2013209.","journal-title":"Circulation"},{"issue":"38","key":"7784_CR21","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"3","key":"7784_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236\u20139.","journal-title":"Thromb Haemost"},{"issue":"2020","key":"7784_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5073814","volume":"25","author":"Q Yan","year":"2020","unstructured":"Yan Q, Ning L, Jian Y, et al. Could the novel oral anticoagulants be used for coronary artery aneurysm? Case Rep Med. 2020;25(2020):1\u20134.","journal-title":"Case Rep Med"},{"issue":"4","key":"7784_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ihj.2024.07.001","volume":"76","author":"A Amirpour","year":"2024","unstructured":"Amirpour A, Zavar R, Danesh M, et al. Anticoagulant and antiplatelet treatment effects on the incidence of major cardiovascular events in patients with coronary artery ectasia: an updated systematic review. Indian Heart J. 2024;76(4):247\u201353.","journal-title":"Indian Heart J"},{"key":"7784_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ahj.2024.11.012","volume":"281","author":"D Araiza-Garaygordobil","year":"2025","unstructured":"Araiza-Garaygordobil D, Gopar-Nieto R, Sierra-Lara Mart\u00ednez JD, et al. A randomized trial of antithrombotic therapy in patients with acute coronary syndrome and coronary ectasia. Am Heart J. 2025;281:103\u201311.","journal-title":"Am Heart J"},{"key":"7784_CR26","doi-asserted-by":"crossref","unstructured":"Azarboo A, Daneshvar MS, Abroy AS, et al. Antithrombotic therapy in adults with ectatic coronary artery disease: a systematic review and network meta-analysis. Egypt Heart J [Internet]. 2025 Jan 22 [cited 2025 Jul 17];77(1).","DOI":"10.1186\/s43044-025-00612-8"},{"issue":"3","key":"7784_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10557-023-07499-0","volume":"38","author":"M Ioannou","year":"2024","unstructured":"Ioannou M, Leonidou E, Chaziri I, et al. Direct oral anticoagulants: navigating through clinical challenges. Cardiovasc Drugs Ther. 2024;38(3):637\u201350. https:\/\/doi.org\/10.1007\/s10557-023-07499-0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"7784_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/ATVBAHA.114.303401","volume":"35","author":"ET Carreras","year":"2015","unstructured":"Carreras ET, Mega JL. Role of oral anticoagulants in patients after an acute coronary syndrome. Arterioscler Thromb Vasc Biol. 2015;35(3):520\u20134.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7784_CR29","doi-asserted-by":"crossref","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non\u2013ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation [Internet]. 2016 Sep 6 [cited 2024 May 20];134(10).","DOI":"10.1161\/CIR.0000000000000404"},{"issue":"7","key":"7784_CR30","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s10554-023-02835-9","volume":"39","author":"H Yu","year":"2023","unstructured":"Yu H, Dai J, Tang H, et al. Characteristics of coronary artery ectasia and accompanying plaques: an optical coherence tomography study. Int J Cardiovasc Imaging. 2023;39(7):1357\u201366.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"9683","key":"7784_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"J Mega","year":"2009","unstructured":"Mega J, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29\u201338.","journal-title":"Lancet"},{"key":"7784_CR32","unstructured":"Hamed M. Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens [Internet]. National Library of Medicine; 2023 Feb. Report No.: NCT05718531. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05718531."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07784-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:24Z","timestamp":1778649684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7784"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07784-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"15 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable. This study was retrospective in nature, and informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable. This study did not include any identifiable individual data, and consent for publication was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"DAG reports speaking fees for Abbott, Asofarma, AstraZeneca, Boehringer Ingelheim, Bayer, Lundbeck, Novartis, Novo Nordisk, Silanes, and Servier. Advisory board: Silanes, Servier, Novartis, Novo Nordisk. Research grants: Novartis, Novo Nordisk. RGN reports speaking fees for Novartis and Asofarma. JDSLM reports speaking fees from Bayer, Novartis, and Novo Nordisk. AAM reports speaker fees from Asofarma, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, and Novo Nordisk. The rest of the authors do not report any relevant conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}